Raymond James set a $10.00 price target on IMV (NYSE:IMV) in a research report released on Tuesday morning, BayStreet.CA reports. The firm currently has an outperform rating on the stock.
Several other equities analysts have also weighed in on IMV. HC Wainwright restated a buy rating and set a $11.50 price objective on shares of IMV in a research report on Wednesday, June 12th. Zacks Investment Research upgraded shares of IMV from a hold rating to a buy rating and set a $2.75 price objective for the company in a research report on Wednesday, August 14th. Finally, Echelon Wealth Partners restated a buy rating on shares of IMV in a research report on Tuesday, June 4th. Five research analysts have rated the stock with a buy rating, IMV has an average rating of Buy and an average target price of $8.81.
Shares of NYSE:IMV traded down $0.06 during trading hours on Tuesday, hitting $2.77. 3,025 shares of the company’s stock traded hands, compared to its average volume of 21,694. IMV has a 52 week low of $2.25 and a 52 week high of $7.07. The company’s fifty day simple moving average is $2.89 and its two-hundred day simple moving average is $3.33.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada boosted its holdings in shares of IMV by 3.6% in the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after buying an additional 3,453 shares during the period. Citadel Advisors LLC acquired a new position in shares of IMV in the second quarter worth about $37,000. Morgan Stanley boosted its holdings in shares of IMV by 260.5% in the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after buying an additional 65,300 shares during the period. Bank of Montreal Can boosted its holdings in shares of IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after buying an additional 13,228 shares during the period. Finally, FIL Ltd boosted its holdings in shares of IMV by 6.6% in the first quarter. FIL Ltd now owns 2,862,000 shares of the company’s stock worth $11,458,000 after buying an additional 177,000 shares during the period.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Featured Article: Why do analysts give a neutral rating?
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.